Anti cd3 bv605

Flow cytometry analysis of T-cell phenotype was performed according to the protocols as previously described. [21] [22] [23] Monoclonal antibodies used in this study including anti-CD3-BV605, anti-CD45-PE, anti-CD4-BV421, anti-CD8-APC-R700 anti-CD95-DX2, anti-CD28-CD28.2, anti-HLA-DR-PE-Cy7, anti-CD69-APC and anti-CCR5-PE, were purchased from BD Biosciences (San Jose, CA, USA). Anti-CD38-FITC was obtained from StemCell Technologies (Vancouver, BC, Canada). Anti-CD25-APC was from Biolegend (San Diego, CA, USA), and anti-CD127-PE was a product of Invitrogen (Carlsbad, CA, USA). CD4 + T cell differentiation was identi ed in terms of CD28 and CD95 expression, as CD28 + CD95 + CD4 + T cell de ned as central memory CD4 + T cell (CD4 + Tcm) and CD28 + CD95 -CD4 + T cell as effector memory CD4+ T cell (CD4 + T EM ). CD28 + CD95 + CD8 + T cell was de ned as CD8 + T CM cell whereas CD28 + CD95 -CD8 + T cell was CD8 + T EM cell. In addition, expression of CD25 and CD127 were measured to evaluate regulatory T Cells (Tregs). Activation markers HLA-DR, CD38 and CD69 were measured on CD4 + and CD8 + T cells, and CD4 + CCR5 + T cells were de ned as SIV-infected cells. All dates were acquired and analyzed on a ow cytometer (FACSCanto; Becton Dickinson).